Antiatherogenic Properties of tert-Butylhydroquinone

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2004
Program:
STTR
Phase:
Phase I
Contract:
1R41HL076925-01
Award Id:
70970
Agency Tracking Number:
HL076925
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
BIOINVENTIONS, LLC, 2109 W MARKET ST, STE 120, JOHNSON CITY, TN, 37604
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
WILLIAMSTONE
(423) 439-8762
stone@etsu.edu
Business Contact:
WILLIAMSTONE
(423) 439-8762
BILLSTON@BIOINVENTIONSLLC.COM
Research Institute:
EAST TENNESSEE STATE UNIVERSITY

EAST TENNESSEE STATE UNIVERSITY
Johnson City, TN, 37601

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and triglycerides in a rat model. TBHQ is phenolic antioxidant commonly used as a food preservative. A patent, "Method for Reducing Blood Cholesterol and/or Blood Triglycerides," was subsequently obtained. The long-term objective of this research proposal is to determine the antiatherogenic potential of TBHQ and advance its commercial development. Our specific aims are to test the efficacy of TBHQ in: (1) reducing aortic atherosclerosis; (2) lowering plasma lipid levels; (3) promoting a less atherogenic lipoprotein profile and; (4) reducing plasma levels of C-reactive protein (CRP). Elevated levels of CRP are a risk factor for cardiovascular disease. In our phase I experiments, we will use the apoE knockout (apoE-/-) mouse model since it has been extensively used to study the antiatherogenic potential of other phenolic antioxidants. Our preliminary market analysis suggests that TBHQ could have a potential market of $100 million per year as a lipid-lowering agent. Commercial development should be accelerated since NIH has already conducted extensive toxicological studies with TBHQ.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government